Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 27,806	$ 13,806
Accounts receivable, net of allowance for credit losses of $3,919 and $4,068 at 2021 and 2020, respectively	86,567	83,192
Inventories	39,117	38,151
Prepaid expenses	13,107	14,797
Income taxes receivable	13,374	9,675
Other current assets	5,846	6,227
TOTAL CURRENT ASSETS	185,817	165,848
PROPERTY, PLANT AND EQUIPMENT, net	113,491	115,293
RIGHT OF USE ASSETS	70,295	66,385
INTANGIBLES, net	8,423	8,583
GOODWILL	99,445	99,445
DEFERRED TAX ASSETS, net	67,966	72,775
OTHER ASSETS	39,009	40,250
TOTAL ASSETS	584,446	568,579
CURRENT LIABILITIES:
Accounts payable	25,500	23,028
Accrued payroll and related costs	23,063	26,526
Taxes other than payroll and income	4,497	6,556
Unearned revenues	5,864	5,457
Operating lease liabilities	12,357	11,437
Income taxes payable	7,423	8,347
Other current liabilities	6,829	8,399
TOTAL CURRENT LIABILITIES	85,533	89,750
LONG-TERM DEBT, net	208,166	259,433
LONG-TERM OPERATING LEASE LIABILITIES	58,635	56,108
DEFERRED COMPENSATION	38,005	39,145
DEFERRED TAX LIABILITIES, net	20,480	20,585
OTHER LONG-TERM LIABILITIES	27,581	27,985
COMMITMENTS AND CONTINGENCIES
EQUITY:
Preference shares, EUR 0.02 par value; 6,000,000 shares authorized, none issued or outstanding	0	0
Common shares, EUR 0.02 par value; 200,000,000 shares authorized, 46,454,264 issued and 46,240,481 outstanding at 2021 and 44,796,252 issued and 44,572,801 outstanding at 2020	1,188	1,148
Additional paid-in capital	103,358	41,184
Retained earnings	58,115	50,456
Accumulated other comprehensive income (loss)	(7,861)	(7,200)
Treasury shares, at cost, 213,783 at 2021 and 223,451 at 2020	(12,916)	(14,075)
Total Core Laboratories N.V. shareholders' equity	141,884	71,513
Non-controlling interest	4,162	4,060
TOTAL EQUITY	146,046	75,573
TOTAL LIABILITIES AND EQUITY	$ 584,446	$ 568,579